New-Onset of Crohn's Disease Is Associated with Antistreptolysin O Positive Titers.
ASO
Crohn’s disease
IBD
group A Streptococcus
inflammatory bowel disease
new-onset
antistreptolysin O
Journal
Clinical and experimental gastroenterology
ISSN: 1178-7023
Titre abrégé: Clin Exp Gastroenterol
Pays: New Zealand
ID NLM: 101532800
Informations de publication
Date de publication:
2020
2020
Historique:
received:
14
01
2020
accepted:
07
04
2020
entrez:
5
6
2020
pubmed:
5
6
2020
medline:
5
6
2020
Statut:
epublish
Résumé
Different infectious agents have been presumed to be candidates acting as an etiologic factor or trigger of Crohn's disease (CD). Group A Data for antistreptolysin O (ASO) level, throat culture for GAS, and history of streptococcal infection were collected from 91 patients with CD that were divided into three groups including; new-onset CD, CD in remission and active CD. The data were compared with the control group. All participants had negative results of throat culture for GAS and had no history of documented streptococcal infection in the past year. Our results indicate that new-onset CD, but not CD in remission or active CD, is associated with significantly increased positive ASO compared to controls. Half of the patients in the new-onset CD group were ASO positive, which was significantly higher compared to the control group in a univariant (OR: 4.00; 95% CI 1.27-12.58; P=0.02) and multivariant analysis (OR: 4.41; 95% CI 1.35-14.37; P=0.014). Our study is the first to focus on ASO levels in patients with CD and to demonstrate a significant association between ASO and new-onset of CD. Large prospective randomized controlled studies are needed to confirm the validity of this data and to further clarify the clinical significance of our findings.
Identifiants
pubmed: 32494182
doi: 10.2147/CEG.S245770
pii: 245770
pmc: PMC7227782
doi:
Types de publication
Journal Article
Langues
eng
Pagination
187-191Informations de copyright
© 2020 Bermont et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
BMJ. 1988 Oct 29;297(6656):1105-6
pubmed: 3143445
Aliment Pharmacol Ther. 2016 Jun;43(12):1300-10
pubmed: 27117843
J Crohns Colitis. 2019 Feb 1;13(2):144-164
pubmed: 30137275
Sleep. 2009 Aug;32(8):979-83
pubmed: 19725248
Gut. 2006 Nov;55(11):1667-9
pubmed: 16687433
Gastroenterology. 1995 Mar;108(3):911-6
pubmed: 7875495
Am J Med. 1948 Jul;5(1):3-23
pubmed: 18867849
Am J Gastroenterol. 2006 Oct;101(10):2410-22
pubmed: 16952282
Gut. 2005 Sep;54(9):1232-6
pubmed: 16099791
J Crohns Colitis. 2017 Jan;11(1):3-25
pubmed: 27660341
World J Gastroenterol. 2016 Jan 21;22(3):1304-10
pubmed: 26811667
F1000Prime Rep. 2015 Apr 02;7:44
pubmed: 26097717
J Dermatol. 1977 Oct;4(5):187-91
pubmed: 15461348
Clin Gastroenterol Hepatol. 2008 Oct;6(10):1105-11
pubmed: 18619921
Ann Trop Paediatr. 1999 Sep;19(3):253-5
pubmed: 10715710
Medicine (Baltimore). 2016 Jul;95(28):e4233
pubmed: 27428230
Am J Gastroenterol. 2006 Mar;101(3):645-52
pubmed: 16464223
J Clin Microbiol. 1984 Nov;20(5):966-71
pubmed: 6511878
Indian Pediatr. 1992 Dec;29(12):1491-4
pubmed: 1291494
Arch Dermatol. 1992 Jan;128(1):39-42
pubmed: 1739285
Int J Med Microbiol. 2002 Sep;292(3-4):185-93
pubmed: 12398209
Gastroenterology. 2006 Apr;130(4):1069-77
pubmed: 16618401
Scand J Gastroenterol Suppl. 1989;170:2-6; discussion 16-9
pubmed: 2617184
Int J Rheum Dis. 2012 Feb;15(1):78-85
pubmed: 22324950
Gut. 2013 May;62(5):683-8
pubmed: 22842615
Gastroenterology. 1995 May;108(5):1396-404
pubmed: 7729631
J Clin Invest. 2004 May;113(9):1296-306
pubmed: 15124021
Clin Microbiol Rev. 2014 Apr;27(2):264-301
pubmed: 24696436
Acta Clin Belg. 2011 Nov-Dec;66(6):410-5
pubmed: 22338301
Gut. 2007 Oct;56(10):1394-403
pubmed: 17456509